Latest research on Bromocriptine

Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.

Latest findings

Case reports of experimental treatment with Dopamine agonists such as Bromocriptine have also been inconsistent, in some showing improvement in the in vitro immune function and HAQ disability scores, whereas in others exhibiting nonsignificant improvement as compared with placebo [17, 18]. [source, 2016]
In December 1996 Bromocriptine 3.75 mg/day was indicated without normalization of IGF-I. [source, 2016]
Two years later, he was medicated with Cabergoline 0.5 mg/week with poor tolerance and response; therefore, he returned to Bromocriptine 5 mg/day. [source, 2016]
Two weeks after the 6-OHDA injection, the animals were briefly (<3 min) anesthetized with 2 % Halothane using a mask and received for intracisternal administration Bromocriptine (7 μg/kg dissolved in 5 μl vehicle; Sigma-Aldrich, France) or the vehicle alone (5 μl of 0.9 % saline) according to our previous results [25]. [source, 2016]
For i.p. injection we used Bromocriptine (1 mg/kg) and SKF81297 (3 mg/kg dissolved in 0.9 % saline; Sigma-Aldrich, France) concentrations [25]. [source, 2016]
Intraperitoneal administration of Bromocriptine induced a significant, dose dependent (0.1 mg and 1 mg/Kg) decrease in pain scores in CCI-IoN group when compared to sham (Fig. 2a) and its effect lasted for 6 h. [source, 2016]
Intracisternal administration of Bromocriptine (Fig. 2b) decreased significantly the SMA score when compared to sham (saline-injected). [source, 2016]
Bromocriptine effect lasted for 20 min. [source, 2016]
Intraperitoneal administration of Bromocriptine (Fig. 2c) induced a significant dose dependent decrease in SMA score in CCI-IoN + 6-OHDA lesioned group compared to that of sham. [source, 2016]
Intracisternal administration of Bromocriptine (Fig. 2d) decreased significantly the SMA score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. [source, 2016]